Nanoliposomal irinotecan for use in treating small cell lung cancer

Number of patents in Portfolio can not be more than 2000

United States of America

PATENT NO 11318131
APP PUB NO 20190167661A1
SERIAL NO

16302050

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Novel therapies for the treatment of small cell lung cancer (SCLC) include the administration of an antineoplastic therapy consisting of liposomal irinotecan administered once every two weeks, optionally including the administration of other non-antineoplastic agents to the patient such as the administration of a corticosteroid and an anti-emetic to the patient prior to the administration of the irinotecan liposome.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IPSEN BIOPHARM LTDWREXHAM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adiwijaya, Bambang Belmont, US 8 27
Fitzgerald, Jonathan Basil Arlington, US 43 295
Lee, Helen Cambridge, US 30 712

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Nov 3, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 3, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 3, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00